Optical biosensors have led to significant advancements in virus detection and imaging capabilities. Coupled with advanced instrumentation, they have enabled higher sensitivities while increasing the rate at which samples can be tested. These techniques can be developed into point-of-care (POC) diagnostics for viral detection and are
Read MoreSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiology of coronavirus disease 2019 (COVID-19), is readily transmitted person to person. Optimal control of COVID-19 depends on directing resources and health messaging to mitigation efforts that are most likely to prevent transmission, but the relative importance of
Read MoreCoronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has caused a global pandemics. To facilitate the detection of SARS-CoV-2 infection, various RT-LAMP assays using 19 sets of primers had been developed, but never been compared.
Read MoreLateral flow devices for asymptomatic mass testing are proving controversial. At the heart of the matter is a flawed process, with the decision to implement society-wide “Moonshot” testing made before robust field evaluations of the tests were completed. Subsequent selective emphasis of unrealistic performance estimates has caused confusion.
Read MoreAcute coronavirus disease 2019 (COVID-19) is primarily diagnosed via reverse transcription-polymerase chain reaction (RT-PCR) detection of viral genetic material. However, considering the three primary modes of transmission of SARS-Cov-2 i.e., contact, droplet and aerosol routes, various types of samples have been suggested for the purpose of
Read MoreClear Health Pass™ LLC acts as Authorized Representative of tribal, federally chartered corporations formed under Section 17 of the Indian Reorganization Act (IRA), U.S.C. Title 25.
(800) 266-7207
(212) 313-9529
© 2023 Clear Health Pass Holdings™, LLC., All trademark references are trademarks of either the Clear Health Pass Holdings, LLC or their respective owners.
